Drugs / Auto-CD34+ cells
Auto-CD34+ cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01508910 | Apr 2012 → Nov 2015 | coronary artery disorder, myocardial ischemia | Lisata Therapeutics, Inc. | Completed | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Auto-CD34+ cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01508910 ↗ |
| Known as | Auto CD34+ Stem Cells | “Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina” NCT01508910 ↗ |
| Known as | autologous CD34(+) cells | “IM administration of autologous CD34(+) cells has been associated consistently with improvements in functional capacity and angina symptoms in early phase clinical trials.” PMID 27491607 ↗ Aug 2016 |
| Modality | Cell therapy | “RENEW will be the first adequately powered study aimed at definitively determining the efficacy of a cell therapy (intramyocardially delivered autologous CD34(+) cells)” PMID 23708155 ↗ Apr 2013 |
| Route | Other | “intramyocardial injection of 1 × 10(5) autologous CD34(+) cells/kg” PMID 23708155 ↗ Apr 2013 |